Publications by authors named "N Goldschmidt"
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR T. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression.
View Article and Find Full Text PDFBackground: Bone marrow examination (BME) is the gold standard of diagnosing myelodysplastic syndromes (MDS).
Problems: it is invasive, painful, causing possible bleeding, inaccurate (aspirate hemodilution), and subjective (inter-observer interpretation discordance). We developed non-invasive diagnostic tools: A logistic regression formula [LeukRes 2018], then a web algorithm using 10 variables (age, gender, Hb, MCV, WBC, ANC, monocytes, PLT, glucose, creatinine) to diagnose/exclude MDS [BldAdv 2021].
Article Synopsis
- A phase II clinical study evaluated the effectiveness of a treatment combo (ibrutinib, bendamustine, and rituximab) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after stem cell transplants or in elderly patients.
- The study showed a 49.1% overall response rate among patients who received at least one cycle, with better outcomes for those with relapsed disease (72.3%) versus refractory disease (37.8%).
- Patients experiencing complete or partial responses had significantly longer median overall survival of 28.1 months, while common side effects included fatigue, diarrhea, and nausea, indicating that the treatment is both safe and effective for those needing potential transplantation.
Objectives: The study aim was to create an updated valid translation into Hebrew of the AHRQ's survey on patient safety culture for hospitals, version 2.0. It also suggested a supplementary section about workers' safety.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to investigate how the influx of COVID-19 patients in Israeli hospitals affected compliance with quality care indicators during the pandemic.
- Data was collected on hospital quality indicators and correlated with COVID-19 inpatient volumes from July 2019 to June 2022.
- Results showed that compliance with five key quality indicators remained stable, indicating hospitals successfully maintained care standards despite high COVID-19 patient numbers.